Monopar Therapeutics Inc. Gains 64.58%

Thu, Sep 12, 2024 at 05:30 PM
Monopar Therapeutics Inc. Gains 64.58%

Monopar Therapeutics Inc. (MNPR:NASDAQ) shot up at $3.95, a gain of 64.6%. On Wed, Sep 11, 2024, MNPR:NASDAQ hit a New 2-Week Intraday High of $2.47. The stock got featured on our News Catalysts scanner on Thu, Sep 12, 2024 at 10:32 AM in the 'BIOTECH' category. From Wed, Aug 28, 2024, the stock recorded 55.56% Up Days and 30.00% Green Days

The share price of the company has been moving sideways in recent weeks.

About Monopar Therapeutics Inc. (MNPR:NASDAQ)

Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.

Share
Get Lifetime 50% Off Premium Subscription
$19.99 USD
Limited-Time Discount
$9.99 USD
monthly
Signup 7 Days Trial. No Credit Card Required!
Ever wanted to explore stocks that have recently spiked... stocks moving sideways... gaps... or other trends? You're in the right place! Check StockTreats features.